Nonsteroidal anti-inflammatory drugs, aspirin, and gastrointestinal prophylaxis: An ounce of prevention

Reviews in Gastroenterological Disorders

Volumn 5, Issue SUPPL. 2, 2005, Pages

  Scheiman, James M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Gastrointestinal bleeding; Gastroprotection; Peptic ulcer disease; Proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; LANSOPRAZOLE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARECOXIB; PLACEBO; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB; VALDECOXIB;

ABDOMINAL CRAMP; ADENOMATOUS POLYP; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSPEPSIA; ECONOMIC EVALUATION; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART PROTECTION; HEARTBURN; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; META ANALYSIS; NAUSEA; PATHOPHYSIOLOGY; PEPTIC ULCER; PRACTICE GUIDELINE; PREVALENCE; PROPHYLAXIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; STOMACH PROTECTION; STROKE; THROMBOEMBOLISM; UNITED STATES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; HUMANS; PEPTIC ULCER; PEPTIC ULCER HEMORRHAGE; PROTON PUMPS; TREATMENT OUTCOME;

EID: 29444447346     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Scheiman JM. Gastroduodenal safety of cox-2 specific inhibitors. Curr Pharm Des. 2003; 9:2197-2206.
2. Mamidani M, Juurlink LN, Kopp A, et al. Gastrointestinal bleeding after the introduction of COX 2 inhibitors: an ecological study. BMJ. 2004;328:1415-1416.
3. Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAIDS-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology. 2000;119:706-714.
4. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. Br Med J. 2000;321:1183-1187.
5. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136:161-172.
6. Cox ER, Frisse M, Behm A, Fairman KA. Over the counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users. Arch Intern Med 2004;164:1243-1245.
7. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomized controlled trials. Br Med J. 2002;325:619.
8. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The Class Study: a randomized controlled trial. JAMA. 2000;284:1247-1255.
9. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004;364:675-684.
10. Mamdani M, Juurlink DN, Lee DS, et al. Cyclooxygenase-2 inhibitors versus nonselective nonsteroidal antiinflammatory drugs and congestive heart failure outcomes in elderly patients: a poulation-based cohort study. Lancet. 2004;363:1751-1756.
11. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520-1528.
12. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092-1102.
13. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352:1081-1091.
14. Solomon SD, McMurray JJ, Pfeffer AM, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071-1080.
15. Jüni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta analysis. Lancet. 2004;364:2021-2029.
16. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med. 1998;338:727-734.
17. Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of non-steroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med. 2002;162:169-175.
18. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002;347:2104-2110.
19. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology. 2004;127: 1038-1043.
20. Scheiman JM, Yeomans N, Hawkey CJ, et al. Esomeprazole reduces gastric and duodenal ulcer development among high risk NSAID users [abstract]. Am J Gastroenterol. 2003;98:S52.
21. Scheiman JM, Vakil N, Hawkey C, et al. Esomeprazole prevents gastric and duodenal ulcers in at-risk patients on continuous non-selective or COX-2-selective NSAID therapy. Gastroenterology. 2004;126(suppl 2):A-82.
22. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346:2033-2038.
23. Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med. 2005; 352:238-244.
24. Fendrick AM, Bandekar RR, Chernew ME, Scheiman JM. Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: a decision analysis. Arthritis Rheum. 2002:47:36-43.
25. Spiegel BM, Targownik L, Dulai GS, Gralnek IM. The cost effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med. 2003;138:795-806.
26. Spiegel BM, Chiou CF, Ofman JJ. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups. Arthritis Rheum. 2005;53:185-197.
27. Fendrick AM. COX-2 inhibitor use after Vioxx: careful balance or end of the rope? Am J Manag Care. 2004;10:740-741.